Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada.

Data from the Colorado Central Cancer Registry shows Routt County had the highest rate of prostate cancer among all Colorado counties during the three-year time span between 2020 and 2022. That fact should encourage

Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, expanding its presence in treatments targeting solid tumors and prostate cancer. This marks the medtech conglomerate's second major deal this year,